Viking Therapeutics Inc (VKTX)

[greens12]

"We are excited about the initial results from this study, as they demonstrate promising effects in a model of NASH that we believe reflects many characteristics of the disease in humans," said Brian Lian, Ph.D., chief executive officer of Viking. "The robust effect across multiple disease metrics, including reductions in collagen and lipotoxic lipids suggests potential benefits on endpoints important in NASH. The observed reductions in hepatic collagen content and fibrosis, by morphometric analysis, are particularly noteworthy, as these data represent the first quantitative histologic evidence that treatment with a thyromimetic agent can potentially improve NASH-related fibrosis. These results provide further support for the development of VK2809 in these settings."